A phase II trial of docetaxel and vinorelbine in patients with hormone-refractory prostate cancer

Cancer Chemotherapy and Pharmacology

Volumn 56, Issue 2, 2005, Pages 199-204

  Goodin, Susan ^a,b,c   Rao, Kamakshi V ^b   Kane, Michael ^a,b   Dave, Nisha ^c   Capanna, Terry ^b   Doyle Lindrud, Susan ^b   Engle, Elizabeth ^c   Jin, Lixian ^b   Todd, Mary ^a,b   DiPaola, Robert S ^a,b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c RUTGERS UNIVERSITY   (United States)

Author keywords

Docetaxel; Hormone refractory prostate cancer; Vinorelbine

Indexed keywords

ALKALINE PHOSPHATASE; AMINOTRANSFERASE; BILIRUBIN; DEXAMETHASONE; DOCETAXEL; HORMONE; LIVER ENZYME; NAVELBINE; PROSTATE SPECIFIC ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABNORMALLY LOW SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ALOPECIA; ARTICLE; ATAXIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE PAIN; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DEPRESSION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEVER; HUMAN; LEUKOPENIA; LIVER FUNCTION; MALE; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; PARESTHESIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROTHROMBIN TIME; REFRACTORY PERIOD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TAXOIDS; VINBLASTINE;

EID: 21244468226     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0980-1     Document Type: Article

References (29)

1. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al (2004) Cancer statistics, 2004. CA Cancer J Clin 54(1):8-29
2. DiPaola RS, Patel J, Rafi MM (2001) Targeting apoptosis in prostate cancer. Hematol Oncol Clin North Am 15(3):509-524
3. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC (1996) Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 14:1756
4. Kantoff PW, Halabi S, Conaway M, Picus J, Dirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ (1999) Hydrocortisone with and without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B. J Clin Oncol 17:2506-2513
5. Beer TM, Pierce WC, Lowe BA, Henner WD (2001) Phase II study of weekly docetaxel in symptomatic androgen-independent prostate cancer. Ann Oncol 12:1273-1279
6. Picus J, Schultz M (1999) Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: preliminary results. Semin Oncol 26 [5 Suppl 17]:14-18
7. Friedland D, Cohen J, Miller R Jr, et al (1999) A phase II trial of docetaxel (Taxotere) in hormone-refractory prostate cancer: correlation of antitumor effect to phosphorylation of bcl-2. Semin Oncol 26 [5 Suppl 17]:19-23
8. Roth BJ, Yeap BY, Wilding GW, et al (1993) Taxol in advanced hormone refractory carcinoma of the prostate. Cancer 72:2457-2460
9. Trivedi C, Redman B, Flaherty LE, et al (2000) Weekly 1-h infusion paclitaxel: clinical feasibility and efficacy in patients with hormone-refractory prostate carcinoma. Cancer 89:431
10. Hudes G, Ross E, Roth B, et al (2002) Improved survival for patients with hormone-refractory prostate cancer receiving estramustine-based antimicrotubule therapy: final report of a Hoosier Oncology Group and Fox Chase Network phase III trial comparing vinblastine and vinblastine plus oral estramustine phosphate (abstract). Proc Am Soc Clin Oncol 21:704
11. Berry W, Gregurich M, Dakhil S, Hathorn J, Asmar L (2001) Phase II randomized trial of weekly paclitaxel (Taxol) with or without estramustine phosphate in patients with symptomatic, hormone-refractory, metastatic carcinoma of the prostate. Proc Am Soc Clin Oncol 20:696
12. Hudes GR, Obasaju C, Chapman A, Gallo J, McAleer C, Greenberg R (1995) Phase I study of paclitaxel and estramustine: preliminary activity in hormone-refractory prostate cancer. Semin Oncol 22 [Suppl 6]:6-11
13. Hudes GR, Nathan F, Khater C, et al (1997) Phase II trial of 96-h paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 15:3156
14. Hudes G, Manola J, Conroy T, et al (2001) Phase II study of weekly paclitaxel by 1-h infusion plus reduced-dose oral estramustine in metastatic hormone-refractory prostate carcinoma. Proc Am Soc Clin Oncol 20:175a
15. Petrylak DP, Macarthur RB, O'Connor J, et al (1999) Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol 17:958-967
16. Kreis W, Budman DR, Fetten J, et al (1999) Phase I trial of combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone-refractory carcinoma. Ann Oncol 10:33
17. Savarese D, Halabi S, Hars V, et al (2001) Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol 19:2509-2516
18. Petrylak DP, Shelton GB, England-Owen C, et al. (2000) Response and preliminary survival results of a phase II study of docetaxel + estramustine in patients with androgen-independent prostate cancer (abstract 1312). Proc Am Soc Clin Oncol 19
19. Copur MS, Tarantolo SR, Hauke R, et al (2000) Weekly estramustine, Taxotere, and dexamethasone in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 19:347a
20. Kelly WK, Curley T, Slovin S, et al (2001) Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 19:44-53
21. Petrylak DP, Tangen C, Hussain M, et al (2004) SWOG99-16: randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/ prednisone (P) in men with androgen-independent prostate cancer (AIPCA). Proc Am Soc Clin Oncol 2:3
22. Eisenberger MA, DeWit R, Berry W, et al (2004) A multicenter phase III comparison of docetaxel (D) and prednisone (P) and mitoxantrone (MTZ) and P in patients with hormone-refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol 2:4
23. Hussain M, Petrylak D, Fisher E, et al (1999) Docetaxel and estramustine versus mitoxantrone and prednisone for hormone-refractory prostate cancer: scientific bases and design of Southwest Oncology Group Study 9916. Semin Oncol 26 [5 Suppl 17]:55-60
24. Oudard S, Caty A, Humblet Y, et al (2001) Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Ann Oncol 12(6):847-852
25. Hino H, Kobayashi K, Hayashihara K, et al (1995) In vitro combination effect of docetaxel with vinca alkaloids on cancer cell lines. Proc Am Assoc Cancer Res 36:299
26. Aoe K, Ueoka H, Kiura K, et al (1996) Synergistic effect of docetaxel and vinorelbine against in vitro growth of a human small-cell lung cancer cell line. Proc Am Assoc Cancer Res 37:375
27. Bissery MC, Vrignaud P, Bayssas M, Lavelle F (1995) Preclinical in vivo activity of docetaxel-containing combinations. Proc Am Soc Clin Oncol 14:489
28. Fukuoka K, Arioka H, Iwamoto Y, et al (2001) Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. Lung Cancer 34(3):451-460
29. Halder S, Basu A, Croce CM (1997) Bcl-2 is the guardian of microtubule integrity. J Cancer Res 57:229-233